10 High Profit Margin Stocks to Buy Now
On June 24, Chris Hyzy, Merrill and BofA Private Bank CIO, joined 'Closing Bell' on CNBC to discuss his bullish outlook on the stock market.
Abbott Laboratories (ABT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 11,653,213 | $1,545,798,768 | +4% | 0.67% |
| 2. | Diamond Hill Capital Ric Dillon | 6,073,765 | $805,684,927 | -8% | 3.69% |
| 3. | 2,172,000 | $288,115,800 | -30% | 0.05% | |
| 4. | Sessa Capital John Petry | 1,806,988 | $239,696,958 | -55% | 9.35% |
| 5. | AQR Capital Management Cliff Asness | 1,716,693 | $227,118,470 | +15% | 0.23% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $122.50 | 2,040 | $249,900.00 | 7,296 | 2021-02-23 | Filing | |
| $73.40 | 2,000 | $146,798.20 | 52,562 | 2019-04-22 | Filing | |
| $72.32 | 100 | $7,231.50 | 6,400 | 2019-01-31 | Filing | |
| $72.31 | 100 | $7,230.50 | 6,300 | 2019-01-31 | Filing | |
| $72.33 | 1,800 | $130,194.00 | 6,200 | 2019-01-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $129.66 | 2,600 | $337,116.00 | 34,058 | 2025-04-30 | Filing | |
| $136.65 | 200 | $27,329.00 | 71,928 | 2025-03-07 | Filing | |
| $133.82 | 91,167 | $12,199,967.94 | 71,928 | 2025-03-06 | Filing | |
| $138.17 | 949 | $131,123.33 | 74,381 | 2025-03-03 | Filing | |
| $138.17 | 562 | $77,651.54 | 31,970 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 227,790 | $30,981,717 | 1.02% | |
| 2. | 103,879 | $14,128,542 | 1.24% | |
| 3. | 32,760 | $4,455,688 | 2.29% | |
| 4. | 25,859 | $3,517,023 | 0.31% | |
| 5. | 23,831 | $3,241,234 | 0.99% |
News See All
Abbott Laboratories (ABT) Surged Ahead of the Market in 2025 with Steady Earnings Momentum
In the first quarter of 2025, the company delivered strong earnings and outperformed a group of medical device peers, despite challenging conditions driven by tariffs.
15 Best Dividend Stocks of 2025
After underperforming the market in seven of the past eight years, the Morningstar Dividend Leaders Index has made a strong comeback in 2025.
Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation
Abbott Laboratories (NYSE:ABT) ranks among the top stocks for an early retirement portfolio.
Early Retirement Portfolio: Top 15 Stock Picks
The Fed predicted two-quarter-percentage-point decreases this year at its most recent statement in March, which is consistent with current market pricing.
Leerink Partners Begins Coverage on ABT
The company is a Dividend King with 53 consecutive years of dividend growth. Its five-year average annual dividend growth rate sits at nearly 11%.
Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management
Abbott Laboratories (NYSE:ABT) is one of the best stocks to buy for beginners now. On June 10, Tandem Diabetes Care Inc.
10 Best Stocks to Buy For Beginners Now
On June 12, Dan Niles, Niles Investment Management founder and portfolio manager, joined CNBC's 'Squawk Box' to discuss the state of the economy and how he expects the market to catch up to reality later...
Jim Cramer Calls Abbott “Really Excellent”
Abbott Laboratories (NYSE:ABT) is one of the 17 stocks that Jim Cramer commented on.
Jim Cramer Commented on These 17 Stocks
On Friday, Mad Money host Jim Cramer shared his evolving view of Elon Musk’s company as he provided both praise and caution in light of recent developments involving Musk and President Donald Trump.
Billionaire Hedge Funds
